Knight Therapeutics Inc. announces voting results from the Annual Meeting
May 09 2018 - 8:00AM
Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”)
announced today the voting results from the Annual Meeting of the
Shareholders held in Montreal, Quebec (“Meeting”).
Election of Directors
Each director nominee listed in the Management
Information Circular dated March 30, 2018 (“Circular”) was elected
as Director of the Corporation at the Meeting. Shareholders present
in person or represented by proxy at the Meeting voted as
follows:
DIRECTOR Nominee |
Outcome |
Votes For |
% For |
votes Withheld |
% Withheld |
James C. Gale |
Elected |
105,326,121 |
98.26 |
% |
1,865,457 |
1.74 |
% |
Jonathan Ross Goodman |
Elected |
105,489,157 |
98.41 |
% |
1,702,421 |
1.59 |
% |
Samira Sakhia |
Elected |
102,558,068 |
95.68 |
% |
4,633,510 |
4.32 |
% |
Robert N. Lande |
Elected |
106,615,046 |
99.46 |
% |
576,532 |
0.54 |
% |
Sylvie Tendler |
Elected |
106,593,510 |
99.44 |
% |
598,068 |
0.56 |
% |
Meir Jakobsohn |
Elected |
104,127,029 |
97.14 |
% |
3,064,549 |
2.86 |
% |
Sarit Assouline |
Elected |
101,213,051 |
94.42 |
% |
5,978,527 |
5.58 |
% |
Appointment of external
Auditors
Ernst & Young LLP were appointed as external
auditors of the Corporation for the next year by a majority of the
votes cast by the shareholders present or represented by proxy, and
the directors were authorized to determine their remuneration.
Shareholders present in person or represented by proxy at the
Meeting voted as follows:
OUTCOME |
VOTES FOR |
% FOR |
VOTES WITHHELD |
% WITHHELD |
Appointed |
107,364,861 |
98.37 |
% |
1,782,631 |
1.63 |
% |
The results of the final votes regarding all
matters subject to a vote during the Meeting will also be made
available on SEDAR (www.sedar.com).
About Knight Therapeutics
Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing innovative pharmaceutical products for
the Canadian and select international markets. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more
information about Knight Therapeutics Inc., please visit the
company's web site at www.gudknight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared, but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2017. Knight Therapeutics Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information or future events,
except as required by law.
For further information please
contact:
Knight Therapeutics Inc. Samira Sakhia President and Chief
Financial Officer T: 514-678-8930 F: 514-481-4116
info@gudknight.comwww.gudknight.com
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Sep 2023 to Sep 2024